Zacks Investment Research
09 Jul 2026, 19:30 UTC · 2h ago
United Therapeutics Stock Rises 14% YTD: Here's What You Need to Know
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Zacks Investment Research
09 Jul 2026, 19:30 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
United Therapeutics' TETON-1 phase III study for IPF achieved its primary endpoint with statistically significant improvement in lung function. — Successful phase III data is a critical catalyst for drug approval and opens a market that management believes could exceed current primary product revenues.
+0.80The phase III ADVANCE OUTCOMES study for the PAH candidate ralinepag met both primary and secondary endpoints. — Positive late-stage data for a new candidate expands the company's product pipeline and revenue potential.
+0.60United Therapeutics intends to submit a new drug application for ralinepag to the FDA in the second half of 2026. — Provides a concrete timeline for potential commercialization and regulatory milestones.
+0.40Continue reading
6 related stories
Top 1 mover · tap to explore
United Therapeutics' shares have gained 14% year-to-date, significantly outperforming its industry's 0.8% decline. — Confirms strong relative momentum and positive investor sentiment compared to peers.
+0.20Which stocks this story touches
The company has seen significant stock gains driven by major clinical breakthroughs and positive phase III data for Tyvaso and ralinepag.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Zacks Investment Research
5h ago
